All Eyes on ExPEC: A Major Driver of Invasive Disease and Antimicrobial Resistance

Join us for a live, virtual CME/CE/CPE-certified 90-minute symposia to gain expert insights on the burden of extraintestinal E coli (ExPEC), patient populations at risk for invasive disease caused by ExPEC, and prevention strategies, including the current landscape of ExPEC vaccines.

Agenda

  • Introduction
  • ExPEC: A Cause for Concern
  • ExPEC: Who’s at Risk?
  • Great ExPEC’tations: A Path to Reducing Antibiotic Resistance
  • Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Program Director
Lilian Abbo, MD, FIDSA

Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Miami, Florida

Faculty
Julie Ann Justo, PharmD, MS

Clinical Associate Professor
Department of Clinical Pharmacy and Outcomes Sciences
University of South Carolina College of Pharmacy
Infectious Diseases Clinical Pharmacy Specialist
Department of Pharmacy
Prisma Health Richland Hospital
Columbia, South Carolina

Faculty
David van Duin, PhD, FIDSA, FAST

Professor of Medicine
Director, Immunocompromised Host Infectious Diseases Program
Division of Infectious Diseases
University of North Carolina
Chapel Hill, North Carolina

Goal Statement
The goal of this activity is to improve learners’ knowledge and understanding of the burden of ExPEC in key populations, individual and societal benefits of ExPEC prevention, and emerging ExPEC vaccine technologies.

Target Audience
This program is intended for physicians, pharmacists, and other healthcare professionals who care for patients with or at risk for ExPEC infections.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Summarize the burden of ExPEC including epidemiology, pathogenicity, antimicrobial resistance, and risk factors for infection and severity
  • Describe the individual and collective benefits of ExPEC prevention strategies including reduced morbidity and mortality, antibiotic consumption, and antimicrobial resistance
  • Discuss the current landscape of ExPEC vaccines including bacterial targets, emerging technologies, efficacy and safety data, and optimizing uptake in key patient populations

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-195-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.